戻る Agenda
Engaging the Rare Disease Community to Design Clinical Trials
Session Chair(s)
Scott Schliebner, MPH
Senior Vice President, Clinical Development Services
TFS Health Science, United States
In this session, participants will hear several recent examples of how to best engage with different patient communities with respect to clinical trial design.
Learning Objective : Discuss examples of how to best engage with different patient communities with respect to clinical trial design.
Speaker(s)
Nothing About Us, Without Us: Best Practices for Engaging With the Rare Disease Patient Community
Scott Schliebner, MPH
TFS Health Science, United States
Senior Vice President, Clinical Development Services
Enrollment: Using Patient Advocacy Groups to Design a Better Trial and Manage Studies in Rare Diseases
Bruce Wynne, PHARMD
Taiho Oncology, Inc., United States
Senior Director , Clinical Operations
Early Engagement with the Kabuki Syndrome Patient Community to Understand Clinical Phenotype and Unmet Needs
Deborah Hartman, PHD
Takeda Pharmaceuticals International, Inc., United States
Vice President, Global Program Leader